Tyler Flores

Positive Phase II data signals a potential new treatment approach for soft tissue sarcoma, a rare cancer with limited options. Immutep's efti shows promise in early-stage disease, sparking optimism for improved patient outcomes.

Facing past challenges, Palatin Technologies is making strides with a replenished pipeline targeting both common and rare forms of obesity, bolstered by recent funding and strategic partnerships.

Clinical-stage biotech Domain Therapeutics bolsters its leadership with a new CMO as it progresses novel immuno-oncology therapies targeting G protein-coupled receptors. The company's lead candidate, DT-7012, is currently in Phase I/II trials.

Vivani Medical is advancing its ultra-long-acting semaglutide implant, potentially offering a once- or twice-yearly alternative to daily injections for chronic weight management. The company is gearing up for Phase 1 trials and securing funding amidst a booming GLP-1 market.

Phase 3 data for Imunon's IL-12 gene therapy, IMNN-001, signals potential breakthrough in treating advanced ovarian cancer. Can this novel approach overcome the challenges of existing therapies and deliver a much-needed clinical benefit?

Neurvati Neurosciences, backed by Blackstone Life Sciences, appoints Carlos Martin as CCO, signaling a strategic shift towards early commercialization for its pipeline, notably Radiprodil for GRIN-NDD. This move highlights a growing trend of private equity investment in neuroscience.

Positive Phase 2a data and a strengthened financial position position Q32 Bio as a potential disruptor in the alopecia areata space, offering hope for a condition with limited effective therapies.

Positive Phase 2 results for vidofludimus calcium offer a potential breakthrough in progressive multiple sclerosis, but the biotech faces a critical funding challenge to bring the therapy to market.

Despite a Q3 revenue dip, Protalix BioTherapeutics is prioritizing pipeline development, particularly its novel gout treatment, PRX-115, and navigating a competitive landscape for Gaucher disease therapies. Analysts watch closely.

Swedish biotech PeptiSystems has secured growth equity funding to expand its innovative peptide and oligonucleotide manufacturing solutions, tapping into a rapidly expanding market and addressing supply chain vulnerabilities.

Danish biotech Zealand Pharma is rapidly transforming from a research-focused firm to a commercial powerhouse, driven by promising obesity treatments and a major partnership with Roche. New data readouts loom large for 2026.

Onward Therapeutics’ strategic shift to Taiwan signals a broader trend: the rise of Asia as a biotech hub. The company aims to leverage Taiwan’s investment climate and talent pool to accelerate cancer therapy development.

Clinical-stage biotech Onward Therapeutics relocates HQ to Taiwan, seeking funding and a potential public listing amid a surge in the Asian nation's biotech investment and innovation. The move signals a broader trend of companies leveraging Taiwan's growing ecosystem.

Profound Medical has reclaimed Canadian distribution rights for its innovative prostate treatment system, TULSA-PRO, signaling confidence in the technology and a strategic move to capitalize on growing demand. The move is expected to enhance access to this minimally invasive treatment.